Trial Profile

Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 13 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ofranergene obadenovec (Primary) ; Bevacizumab
Indications Glioblastoma; Gliosarcoma
Focus Therapeutic Use
Sponsors VBL Therapeutics

Most Recent Events

08 Jan 2020 According to a VBL Therapeutics media release, data from this trial were published in the peer-reviewed journal Neuro-Oncology.
08 Jan 2020 Results presented in the VBL Therapeutics Media Release.
04 Jun 2019 Results assessing quantitative radiographic results and impact on OS from NCT01260506 and NCT02511405 trials presented at the 55th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com